Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Neuren Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.66 billion
P/E Ratio 11.62
Dividend Yield 0.00%
Shares Outstanding 127.15 million
Earnings per share 1.086
Dividend per share N/A
Year To Date Return 6.32%
Earnings Yield 8.61%
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

  • Should you invest $1,000 in G8 Education Limited right now?

    Before you buy G8 Education Limited shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and G8 Education Limited wasn't one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys...

    See The 5 Stocks *Returns as of 30 April 2025

  • Neuren Pharmaceuticals Ltd (ASX: NEU)
    Latest News

    Excited group of friends sitting on sofa watching sports on TV and celebrating.
    Share Gainers

    Why Eagers, Medibank, Neuren, and Qantas shares are jumping today

    These shares are having a strong session on Thursday. What's going on?

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a rocky but positive start to the week's trading this Monday.

    Read more »

    Ecstatic man giving a fist pump in an office hallway.
    Share Gainers

    Why APA, Aussie Broadband, Neuren, and NIB shares are charging higher today

    These shares are starting the week on a positive note. But why?

    Read more »

    Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
    Healthcare Shares

    2 ASX 200 pharmaceutical shares surging on big US news

    Big news is getting investors excited on Wednesday. Let's find out what is happening.

    Read more »

    Three happy office workers cheer as they read about good financial news on a laptop.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The ASX was back in form this hump day...

    Read more »

    Elderly couple look sideways at each other in mild disagreement
    Share Market News

    Here are the top 10 ASX 200 shares today

    It was a disappointing end to the trading week for ASX investors this Friday...

    Read more »

    A panel of four judges hold up cards all showing the perfect score of ten out of ten
    Share Market News

    Here are the top 10 ASX 200 shares today

    It was a big day for ASX investors, with the market surging higher...

    Read more »

    Shot of a senior scientist looking stressed out while working in a lab.
    Healthcare Shares

    Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

    The market didn't like what this stock had to say this morning...

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why CAR Group, Myer, Neuren, and Yancoal shares are falling today

    These shares are having a tough time on hump day. But why?

    Read more »

    A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
    Growth Shares

    Why these top ASX 200 growth shares could rise 35%+ in 2025

    Analysts are tipping these shares to deliver big returns for investors over the next 12 months.

    Read more »

    A panel of four judges hold up cards all showing the perfect score of ten out of ten
    Share Market News

    Here are the top 10 ASX 200 shares today

    Investors seemed buoyed by the latest inflation figures today...

    Read more »

    View of a business man's hand passing a $100 note to another with a bank in the background.
    Growth Shares

    Invest $10,000 into these ASX 200 shares in January

    Market-beating returns could be on offer from these shares this year according to analysts.

    Read more »

    Frequently Asked Questions

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Neuren Pharmaceuticals Ltd

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    NEU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    09 May 2025 $13.29 $0.49 3.83% 757,061 $13.19 $13.49 $12.81
    08 May 2025 $12.80 $0.18 1.43% 1,193,552 $12.60 $12.89 $12.11
    07 May 2025 $12.62 $0.47 3.87% 752,028 $12.05 $12.70 $12.03
    06 May 2025 $12.15 $-0.15 -1.22% 359,857 $12.30 $12.51 $12.13
    05 May 2025 $12.30 $-0.14 -1.13% 630,459 $12.60 $12.73 $12.10
    02 May 2025 $12.44 $0.64 5.42% 606,889 $11.74 $12.79 $11.67
    01 May 2025 $11.80 $0.14 1.20% 455,202 $11.70 $11.98 $11.61
    30 Apr 2025 $11.66 $0.10 0.87% 608,951 $11.65 $11.72 $11.36
    29 Apr 2025 $11.56 $0.57 5.19% 677,157 $11.00 $11.62 $10.92
    28 Apr 2025 $10.99 $-0.35 -3.09% 560,080 $11.43 $11.59 $10.99
    24 Apr 2025 $11.34 $0.33 3.00% 493,618 $11.16 $11.59 $11.16
    23 Apr 2025 $11.01 $0.62 5.97% 550,515 $10.81 $11.27 $10.61
    22 Apr 2025 $10.39 $-0.14 -1.33% 458,821 $10.45 $10.67 $10.32
    17 Apr 2025 $10.53 $0.36 3.54% 672,718 $10.11 $10.53 $10.11
    16 Apr 2025 $10.17 $-0.81 -7.38% 852,200 $10.86 $10.95 $10.10
    15 Apr 2025 $10.98 $-0.15 -1.35% 1,102,530 $11.20 $11.63 $10.51
    14 Apr 2025 $11.13 $1.94 21.11% 1,675,439 $9.70 $11.20 $9.70

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    16 Apr 2025 Joseph(Joe) Basile Buy 14,500 $153,158
    On-market trade.
    16 Aug 2024 Joseph(Joe) Basile Buy 6,406 $100,766
    On-market trade.
    11 Jun 2024 Joseph(Joe) Basile Buy 5,000 $97,450
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Dianne Margaret Angus Non-Executive Director Jul 2018
    Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. Dianne has created global industry partnerships to yield medical, pharmaceutical and agricultural products. She has also driven the development path for novel neurological pre-clinical agents to late stage clinical assets before the FDA and European regulators. With over twenty five year' experience in ASX and NASDAQ listed companies, she has experience in business development, capital raising and investor relations together with corporate governance and compliance capabilities. She is also a council member of Deakin University.
    Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
    Mr Pilcher has played a central role in all aspects of Neuren's R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB.
    Dr Jenny Lee Harry Non-Executive Director Jul 2018
    Dr Harry has 20 years' experience in executive management of companies in the biotechnology and biopharmaceutical industry and is an accomplished CEO and Managing Director with experience in growing companies from start-up to commercialisation. She has served on Boards of a number of listed and unlisted companies and is currently a Non-Executive Director of Lumitron Technologies Inc.
    Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
    Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in senior roles across industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
    Mr Joseph(Joe) Basile Non-Executive Director Mar 2023
    Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia.
    Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
    -
    Gerry Zhao Chief Business Officer
    -
    Lauren Frazer Chief Financial OfficerCompany Secretary
    -
    Liza Squires Chief Medical Officer
    -
    Clive Blower Chief Operations Officer
    -
    Larry Glass Chief Science Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 17,684,031 13.97%
    Citicorp Nominees Pty Limited 13,225,277 10.45%
    J P Morgan Nominees Australia Pty Limited 12,906,867 10.20%
    Cameron Richard Pty Ltd 4,355,222 3.44%
    BNP Paribas Noms Pty Ltd 4,056,178 3.20%
    Stuart Andrew Pty Ltd 2,790,348 2.20%
    Essex Castle Limited 2,322,678 1.83%
    Linwierik Super Pty Ltd 1,800,000 1.42%
    Smithley Super Pty Ltd 1,584,000 1.25%
    Sharesies Australia Nominee Pty Limited 1,497,609 1.18%
    National Nominees Limited 1,143,545 0.90%
    First Colbyco Pty Ltd 829,200 0.65%
    BNP Paribas Nominees Pty Ltd 765,775 0.60%
    Dr Robin Lance Congreve 671,637 0.53%
    Mjhft Pty Ltd 600,000 0.47%
    Netwealth Investments Limited 560,073 0.44%
    Custodial Services Limited 554,271 0.44%
    HSBC Custody Nominees (Australia) Limited A/C 2 490,918 0.39%
    Emancipayte Pty Ltd 463,141 0.37%
    BNP Paribas Nominees Pty Ltd i 434,135 0.34%

    Profile

    since

    Note